Wells Fargo
MBRX icon

Wells Fargo’s Moleculin Biotech MBRX Stock Holding History

Wells Fargo’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$112 – 7234
2024
Q1 		$112 Hold
1
– – ﹤0.01% 6626
2023
Q4 		$197 Sell
1
-1
-50% -$208 ﹤0.01% 6615
2023
Q3 		$307 Buy
2
+1
+100% +$207 ﹤0.01% 6472
2023
Q2 		$124 Hold
1
– – ﹤0.01% 6826
2023
Q1 		$190 Hold
1
– – ﹤0.01% 6788
2022
Q4 		$552 Hold
1
– – ﹤0.01% 6361
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7080
2022
Q2 		$0 Sell
1
-10
-91% -$5.82K ﹤0.01% 7213
2022
Q1 		$7K Hold
11
– – ﹤0.01% 6386
2021
Q4 		$7K Buy
+11
New +$9.76K ﹤0.01% 6638
2021
Q3 		– Hold
0
– – – 6740
2021
Q2 		– Hold
0
– – – 6691
2021
Q1 		– Hold
0
– – – 6740
2020
Q4 		– Sell
-37
Closed -$65.7K – 6795
2020
Q3 		$67K Buy
37
+2
+6% +$4.25K ﹤0.01% 5404
2020
Q2 		$76K Buy
+35
New +$83K ﹤0.01% 5349
2020
Q1 		– Sell
-1
Closed -$1.7K – 6558
2019
Q4 		$3K Hold
1
– – ﹤0.01% 6123
2019
Q3 		$3K Hold
1
– – ﹤0.01% 6145
2019
Q2 		$3K Buy
+1
New +$2.72K ﹤0.01% 6117
2018
Q2 		– Sell
-2
Closed -$9K – 6466
2018
Q1 		$9K Buy
+2
New +$8.65K ﹤0.01% 5964

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return

Wells Fargo's MBRX Position: Q2 2024 in Review

Wells Fargo sold out of Moleculin Biotech (MBRX) in Q2 2024, closing a stake of 1 share — an estimated $112 sold.

Wells Fargo first reported a position in MBRX in Q1 2018 and held it in 16 quarters. The position peaked at $76K in Q2 2020. 14 funds tracked by Wall St. Rank hold MBRX as of Q2 2024.

  • Wells Fargo reported no remaining Moleculin Biotech position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 1 Moleculin Biotech share in Q2 2024, an estimated $112.
  • Wells Fargo first reported a position in Moleculin Biotech in Q1 2018 and held it in 16 quarters.
  • Wells Fargo's Moleculin Biotech position peaked at $76K in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.